BioXcel Therapeutics, Inc. (BTAI)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about BioXcel Therapeutics, Inc. (BTAI)
Company Performance

Current Price

as of Oct 18, 2024

$0.57

P/E Ratio

N/A

Market Cap

$23.05M

Description

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Metrics

Overview

  • HQNew Haven, CT
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerBTAI
  • Price$0.5658-0.74%

Trading Information

  • Market Cap$23.05M
  • Float79.65%
  • Average Daily Volume (1m)420,451
  • Average Daily Volume (3m)502,516
  • EPS-$3.55

Company

  • Revenue$2.40M
  • Rev Growth (1yr)141.58%
  • Net Income-$8.30M
  • Gross Margin87.41%
  • EBITDA Margin-1,447.55%
  • EBITDA-$15.98M
  • EV$98.88M
  • EV/Revenue41.15
  • P/EN/A
  • P/S9.48
  • P/BN/A
Documents
SEC Filings
8-K (2024-10-09)
8-K (2024-09-20)
8-K (2024-09-19)
8-K (2024-09-09)
8-K (2024-09-05)
8-K (2024-08-06)
8-K (2024-07-17)
8-K (2024-07-16)
8-K (2024-06-25)
8-K (2024-06-12)
8-K (2024-05-09)
8-K (2024-04-22)
8-K (2024-04-10)
8-K (2024-03-25)
8-K (2024-03-12)
8-K (2024-02-14)
8-K (2024-02-12)
8-K (2024-02-08)
8-K (2023-12-18)
8-K (2023-12-12)
8-K (2023-12-06)
8-K (2023-11-14)
8-K (2023-10-10)
8-K (2023-10-04)
8-K (2023-09-25)
8-K (2023-09-19)
8-K (2023-09-12)
8-K (2023-09-07)
8-K (2023-08-22)
8-K (2023-08-14)
8-K (2023-06-30)
8-K (2023-06-29)
8-K (2023-05-08)
8-K (2023-04-20)
8-K (2023-03-16)
8-K (2023-03-15)
8-K (2023-03-10)
8-K (2023-03-09)
8-K (2023-02-21)
8-K (2023-02-13)
10-Q (2024-08-06)
10-Q (2024-05-09)
10-Q (2023-11-14)
10-Q (2023-08-14)
10-Q (2023-05-09)
10-K (2024-03-22)
10-K (2023-03-16)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: BioXcel Therapeutics Q3 ($5.51, 0.00) (2023-11-14T14:44:10Z)
Follow-up: BioXcel Therapeutics reports Q3 EPS ($1.72) vs FactSet ($1.27) [9 est, ($1.84)-(0.53)] ($5.51, 0.00) (2023-11-14T12:04:51Z)
BioXcel Therapeutics reports Q3 EPS ($1.72) vs FactSet ($1.27) [9 est, ($1.84)-(0.53)] ($5.51, 0.00) (2023-11-14T12:03:07Z)
BioXcel Therapeutics reports positive overall survival results from single-arm, open-label Phase 2 trial of BXCL701 ($4.84, 0.00) (2023-11-08T12:16:09Z)
BioXcel Therapeutics reports findings from third party audit of data integrity at TRANQUILITY II phase 3 trial site ($2.34, 0.00) (2023-10-25T11:07:22Z)
BioXcel Therapeutics receives permanent J-Code for IGALMI (dexmedetomidine) sublingual film from Centers for Medicare & Medicaid Services ($3.03, 0.00) (2023-10-30T11:05:42Z)
BioXcel Therapeutics discloses receipt of new US patent from pertaining to method of treating agitation associated with bipolar disorders - 8-K ($3.24, 0.00) (2023-12-18T12:25:28Z)
BioXcel Therapeutics announces update on NIDA-funded trial of BXCL501 (sublingual dexmedetomidine) for potential treatment of opioid use disorder (OUD) ($4.64, 0.00) (2023-11-06T12:04:51Z)
Earnings Calls
Earnings Report 2024Q1
Earnings Report (2023-11-14)
Earnings Report (2023-08-14)